NCT05975645 - A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

June 4, 2025

Study Completion Date

June 4, 2025

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG

Penpulimab injection

Penpulimab is an inhibitor of programmed cell death 1 (PD-1).

DRUG

TQB2618 injection

TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3).

DRUG

Anlotinib Hydrochloride Capsules

Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

Trial Locations (8)

The six people's Hospital of Shenyang, Shenyang

Affiliated Cancer Hospital of Harbin Medical University, Harbin

Third Affiliated Hospital of Naval Medical University, Shanghai

Hunan Cancer Hospital, Changsha

The First People's Hospital of Shangqiu City, Shangqiu

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

Affiliated hospital of zunyi medical university, Zunyi

Gansu Wuwei Cancer Hospital, Wuwei